Drug Patents Expiring in 2031

1. List of Abilify Mycite Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11229378 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jul, 2031

(8 years from now)

US9320455 OTSUKA Highly reliable ingestible event markers and methods for using the same
Dec, 2031

(8 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

2. List of Accrufer drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248148 SHIELD TX Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections
Mar, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 25, 2024

Drugs and Companies using FERRIC MALTOL ingredient

NCE-1 date: July, 2023

Market Authorisation Date: 25 July, 2019

Treatment: Method of treating iron deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage

3. List of Acetadote drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9327028 CUMBERLAND PHARMS Acetylcysteine compositions and methods of use thereof
Jul, 2031

(8 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ACETADOTE before it's patent expiration?
More Information on Dosage

4. List of Airduo Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195375 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2031

(8 years from now)

US10022510 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(8 years from now)

US10124131 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US9731087 TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(8 years from now)

US9216260 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(8 years from now)

US10195375

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2031

(8 years from now)

US10124131

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Nov, 2031

(8 years from now)

US10022510

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Nov, 2031

(8 years from now)

US9731087

(Pediatric)

TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
Nov, 2031

(8 years from now)

US9216260

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Dec, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
M Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

5. List of Akynzeo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9271975 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Sep, 2031

(8 years from now)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 10 October, 2014

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy

Dosage: CAPSULE;ORAL

More Information on Dosage

6. List of Alecensa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9126931 HOFFMANN-LA ROCHE Tetracyclic compound
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 6, 2024

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of ALECENSA before it's patent expiration?
More Information on Dosage

7. List of Alunbrig drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9012462 TAKEDA PHARMS USA Phosphorous derivatives as kinase inhibitors
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 28, 2022
Orphan Drug Exclusivity (ODE) May 22, 2027
New Indication (I) May 22, 2023

Drugs and Companies using BRIGATINIB ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

8. List of Angeliq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8906890 BAYER HLTHCARE Very low-dosed solid oral dosage forms for HRT
Oct, 2031

(8 years from now)

Drugs and Companies using DROSPIRENONE; ESTRADIOL ingredient

Market Authorisation Date: 28 September, 2005

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ANGELIQ before it's patent expiration?
More Information on Dosage

9. List of Apadaz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8461137 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Feb, 2031

(8 years from now)

Drugs and Companies using ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 February, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

10. List of Apretude drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR ingredient

NCE-1 date: January, 2025

Market Authorisation Date: 20 December, 2021

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

11. List of Armonair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195375 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2031

(8 years from now)

US9731087 TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(8 years from now)

US10022510 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(8 years from now)

US10124131 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US9216260 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(8 years from now)

US10195375

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2031

(8 years from now)

US9731087

(Pediatric)

TEVA PHARM Dose counter for inhaler having a bore and shaft arrangement
Nov, 2031

(8 years from now)

US10124131

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Nov, 2031

(8 years from now)

US10022510

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Nov, 2031

(8 years from now)

US9216260

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Dec, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

12. List of Aubagio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802735

(Pediatric)

SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Mar, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
M Apr 30, 2024
Pediatric Exclusivity (PED) Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

Market Authorisation Date: 12 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AUBAGIO before it's patent expiration?
More Information on Dosage

13. List of Austedo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8524733 TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733

(Pediatric)

TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Oct, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 3, 2024
New Chemical Entity Exclusivity (NCE) Apr 3, 2022
M Jun 24, 2024
Pediatric Exclusivity (PED) Oct 3, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: October, 2023

Market Authorisation Date: 03 April, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AUSTEDO before it's patent expiration?
More Information on Dosage

14. List of Avycaz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8471025 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 25, 2020
Generating Antibiotic Incentives Now (GAIN) Feb 25, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

15. List of Balversa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8895601 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
May, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9464071 JANSSEN BIOTECH Pyrazolyl quinoxaline kinase inhibitors
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 12, 2024

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: April, 2023

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage

16. List of Barhemsys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10525033 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(8 years from now)

US9889118 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(8 years from now)

US9545426 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Treatment of post-operative nausea and vomiting; Prevention of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

17. List of Baxdela drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7728143 MELINTA Salt and crystalline forms thereof of a drug
Jun, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 19, 2022
New Indication (I) Oct 24, 2022
Generating Antibiotic Incentives Now (GAIN) Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: June, 2026

Market Authorisation Date: 19 June, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

18. List of Belrapzo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 7, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 May, 2018

Treatment: For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma

Dosage: SOLUTION;IV (INFUSION)

How can I launch a generic of BELRAPZO before it's patent expiration?
More Information on Dosage

19. List of Bendeka drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 7, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 December, 2015

Treatment: For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with chronic lymphocytic leukemia; For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma

Dosage: SOLUTION;IV (INFUSION)

How can I launch a generic of BENDEKA before it's patent expiration?
More Information on Dosage

20. List of Besivance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8481526 BAUSCH AND LOMB Fluoroquinolone carboxylic acid molecular crystals
Jan, 2031

(7 years from now)

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 2009

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

21. List of Bevespi Aerosphere drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815258 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
Mar, 2031

(8 years from now)

Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

22. List of Bevyxxa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8404724 PORTOLA PHARMS INC Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Mar, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 23, 2022

Drugs and Companies using BETRIXABAN ingredient

NCE-1 date: June, 2021

Market Authorisation Date: 23 June, 2017

Treatment: Inhibiting coagulation

Dosage: CAPSULE;ORAL

More Information on Dosage

23. List of Binosto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592195 ASCEND THERAPS US Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
Dec, 2031

(8 years from now)

Drugs and Companies using ALENDRONATE SODIUM ingredient

Market Authorisation Date: 12 March, 2012

Treatment: NA

Dosage: TABLET, EFFERVESCENT;ORAL

More Information on Dosage

24. List of Braftovi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8501758 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Mar, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Jul, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 27, 2023
Orphan Drug Exclusivity (ODE) Jun 27, 2025
New Indication (I) Apr 8, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Treatment of melanoma mediated by a b-raf protein kinase; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; Braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test

Dosage: CAPSULE;ORAL

How can I launch a generic of BRAFTOVI before it's patent expiration?
More Information on Dosage

25. List of Breztri Aerosphere drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815258 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
Mar, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Combination (NC) Jul 23, 2023

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 23 July, 2020

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

26. List of Bryhali drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(8 years from now)

US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(8 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 06 November, 2018

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

How can I launch a generic of BRYHALI before it's patent expiration?
More Information on Dosage

27. List of Bydureon Bcise drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895033

(Pediatric)

ASTRAZENECA AB Sustained release formulations using non-aqueous carriers
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
M Feb 15, 2022
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

28. List of Byfavo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10052334 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(8 years from now)

US9827251 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(8 years from now)

US10195210 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(8 years from now)

US10342800 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(8 years from now)

US10722522 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(8 years from now)

US9737547 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 6, 2025

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

NCE-1 date: October, 2024

Market Authorisation Date: 06 October, 2020

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

29. List of Bylvay drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10487111 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(8 years from now)

US9694018 ALBIREO IBAT inhibitors for the treatment of liver disease
Nov, 2031

(8 years from now)

US10093697 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(8 years from now)

US10981952 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(8 years from now)

US10011633 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2026
Orphan Drug Exclusivity (ODE) Jul 20, 2028

Drugs and Companies using ODEVIXIBAT ingredient

NCE-1 date: July, 2025

Market Authorisation Date: 20 July, 2021

Treatment: Method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic)

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

More Information on Dosage

30. List of Cabenuva Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026
New Patient Population (NPP) Mar 29, 2025
New Dosing Schedule (D) Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv infection in adults

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

31. List of Cabometyx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039757 EXELIXIS INC C-Met modulator pharmaceutical compositions
Jul, 2031

(8 years from now)

US10034873 EXELIXIS INC C-met modulator pharmaceutical compositions
Jul, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 17, 2028
New Indication (I) Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of advanced renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's patent expiration?
More Information on Dosage

32. List of Cerdelga drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888547 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Jan, 2031

(7 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Market Authorisation Date: 19 August, 2014

Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 poor metabolizers with 84 mg once daily of eliglustat (equivalent to 100 mg of eliglustat tartrate); Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent to 100 mg of eliglustat tartrate twice per day)

Dosage: CAPSULE;ORAL

How can I launch a generic of CERDELGA before it's patent expiration?
More Information on Dosage

33. List of Cleviprex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103490 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

US10010537 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

US8658676 CHIESI Clevidipine emulsion formulations containing antimicrobial agents
Oct, 2031

(8 years from now)

Drugs and Companies using CLEVIDIPINE ingredient

Market Authorisation Date: 01 August, 2008

Treatment: NA

Dosage: EMULSION;INTRAVENOUS

How can I launch a generic of CLEVIPREX before it's patent expiration?
More Information on Dosage

34. List of Contrave drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033543 NALPROPION Methods of providing weight loss therapy in patients with major depression
Jan, 2031

(7 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's patent expiration?
More Information on Dosage

35. List of Cosela drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10189849 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

US8598197 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

US9957276 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

US8598186 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10927120 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

US10189850 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: February, 2025

Market Authorisation Date: 12 February, 2021

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

36. List of Daklinza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8629171 BRISTOL-MYERS SQUIBB Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
Jun, 2031

(8 years from now)

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

Market Authorisation Date: 24 July, 2015

Treatment: Method of inhibiting hepatitis c virus

Dosage: TABLET;ORAL

More Information on Dosage

37. List of Daurismo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148401 PFIZER Benzimidazole derivatives
Jan, 2031

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 21, 2023
Orphan Drug Exclusivity (ODE) Nov 21, 2025

Drugs and Companies using GLASDEGIB MALEATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 21 November, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

38. List of Dayvigo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8268848 EISAI INC Cyclopropane compound
Sep, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 7, 2025

Drugs and Companies using LEMBOREXANT ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 07 April, 2020

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

More Information on Dosage

39. List of Delstrigo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 30, 2023
New Indication (I) Sep 19, 2022
New Patient Population (NPP) Jan 27, 2025

Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: Treatment of hiv-1 infection in adult patients as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to the individual components of delstrigo; For the treatment of hiv-1 infection in adult patients with no prior antiretroviral treatment history; Treatment of hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed

Dosage: TABLET;ORAL

How can I launch a generic of DELSTRIGO before it's patent expiration?
More Information on Dosage

40. List of Docetaxel drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842770 SHILPA Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
Aug, 2031

(8 years from now)

Drugs and Companies using DOCETAXEL ingredient

Market Authorisation Date: 22 December, 2015

Treatment: Method of administering docetaxel to a subject combining the docetaxel pro-emulsion formulation with an aqueous medium to produce docetaxel emulsion

Dosage: INJECTABLE;INJECTION

More Information on Dosage

41. List of Dovato drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234985 VIIV HLTHCARE Antiviral therapy
Jan, 2031

(7 years from now)

Exclusivity Exclusivity Expiration
New Combination (NC) Apr 8, 2022
New Indication (I) Aug 6, 2023

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 08 April, 2019

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of DOVATO before it's patent expiration?
More Information on Dosage

42. List of Drospirenone drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11123299 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11291633 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11291632 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11351122 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US10987364 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11413249 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US10179140 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US9603860 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US10849857 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US10603281 EXELTIS USA INC Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Jun, 2031

(8 years from now)

US11504334 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

US11478487 EXELTIS USA INC NA
Jun, 2031

(8 years from now)

US11439598 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jun 29, 2025

Drugs and Companies using DROSPIRENONE ingredient

Market Authorisation Date: 29 June, 2022

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage

43. List of Dsuvia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945592 ACELRX PHARMS Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
Jul, 2031

(8 years from now)

Drugs and Companies using SUFENTANIL CITRATE ingredient

Market Authorisation Date: 02 November, 2018

Treatment: NA

Dosage: TABLET;SUBLINGUAL

More Information on Dosage

44. List of Duobrii drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(8 years from now)

US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Apr 25, 2022

Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient

Market Authorisation Date: 25 April, 2019

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

How can I launch a generic of DUOBRII before it's patent expiration?
More Information on Dosage

45. List of Durysta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8629185 ALLERGAN INC 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Jul, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 4, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: NA

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

46. List of Duzallo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216179 IRONWOOD PHARMS INC Treatment of gout and hyperuricemia
Aug, 2031

(8 years from now)

US9956205 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Dec, 2031

(8 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone

Dosage: TABLET;ORAL

More Information on Dosage

47. List of Ecoza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10071054 RESILIA PHARMS Econazole composition and methods of treatment therewith
Aug, 2031

(8 years from now)

Drugs and Companies using ECONAZOLE NITRATE ingredient

Market Authorisation Date: 24 October, 2013

Treatment: NA

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage

48. List of Edarbyclor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387249 AZURITY Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
Jul, 2031

(8 years from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

Market Authorisation Date: 20 December, 2011

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of EDARBYCLOR before it's patent expiration?
More Information on Dosage

49. List of Edluar drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265720 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Feb, 2031

(8 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 13 March, 2009

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of EDLUAR before it's patent expiration?
More Information on Dosage

50. List of Eliquis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326945 BRISTOL MYERS SQUIBB Apixaban formulations
Feb, 2031

(8 years from now)

Drugs and Companies using APIXABAN ingredient

Market Authorisation Date: 28 December, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ELIQUIS before it's patent expiration?
More Information on Dosage

51. List of Enstilar drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617698 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10716799 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US9566286 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US9119781 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10688108 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10660908 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10130640 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US10682364 LEO PHARMA AS Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
Jun, 2031

(8 years from now)

US9119781

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Dec, 2031

(8 years from now)

US10130640

(Pediatric)

LEO PHARMA AS Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Dec, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 30, 2022
Pediatric Exclusivity (PED) Jan 30, 2023

Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient

Market Authorisation Date: 16 October, 2015

Treatment: Plaque psoriasis; Topical treatment of plaque psoriasis in patients 12 years and older

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of ENSTILAR before it's patent expiration?
More Information on Dosage

52. List of Epclusa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 10, 2028
New Strength (NS) Mar 19, 2023
M Apr 27, 2025
New Dosing Schedule (D) Nov 15, 2022
New Patient Population (NPP) Mar 19, 2023
Pediatric Exclusivity (PED) May 15, 2023

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 28 June, 2016

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

53. List of Evzio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10322239 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(8 years from now)

US9474869 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(8 years from now)

US9022022 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(8 years from now)

US8939943 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(8 years from now)

US10143972 KALEO INC Ultrafiltration membrane and a preparation method thereof
May, 2031

(8 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

54. List of Evzio (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8939943 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(8 years from now)

US9022022 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(8 years from now)

US10322239 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(8 years from now)

US9474869 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(8 years from now)

US10143792 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
May, 2031

(8 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

55. List of Fanapt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072742 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Jan, 2031

(7 years from now)

US9074256 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Feb, 2031

(8 years from now)

US9074254 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Dec, 2031

(8 years from now)

Drugs and Companies using ILOPERIDONE ingredient

Market Authorisation Date: 06 May, 2009

Treatment: Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone

Dosage: TABLET;ORAL

How can I launch a generic of FANAPT before it's patent expiration?
More Information on Dosage

56. List of Fetzima drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8481598 ALLERGAN Stable dosage forms of levomilnacipran
Mar, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
M Oct 7, 2022

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: Treatment of major depressive disorder (mdd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of FETZIMA before it's patent expiration?
More Information on Dosage

57. List of Gelnique drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8920392 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Mar, 2031

(8 years from now)

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Market Authorisation Date: 27 January, 2009

Treatment: Treatment of overactive bladder by application of oxybutynin chloride gel to skin

Dosage: GEL;TRANSDERMAL

How can I launch a generic of GELNIQUE before it's patent expiration?
More Information on Dosage

58. List of Giapreza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572856 LA JOLLA PHARMA Method of treating low blood pressure
Jul, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 21 December, 2017

Treatment: Treating refractory hypotension with about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of GIAPREZA before it's patent expiration?
More Information on Dosage

59. List of Giazo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497256 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
Jun, 2031

(8 years from now)

Drugs and Companies using BALSALAZIDE DISODIUM ingredient

Market Authorisation Date: 03 February, 2012

Treatment: Treatment of mildly to moderately active ulcerative colitis in male patients

Dosage: TABLET;ORAL

How can I launch a generic of GIAZO before it's patent expiration?
More Information on Dosage

60. List of Gilotrif drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10004743

(Pediatric)

BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Jan, 2031

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 12, 2025
M Apr 7, 2025
Pediatric Exclusivity (PED) Oct 15, 2023

Drugs and Companies using AFATINIB DIMALEATE ingredient

Market Authorisation Date: 12 July, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of GILOTRIF before it's patent expiration?
More Information on Dosage

61. List of Harvoni drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 28, 2026
New Dosing Schedule (D) Nov 15, 2022

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Market Authorisation Date: 28 August, 2019

Treatment: NA

Dosage: PELLETS;ORAL

More Information on Dosage

62. List of Hysingla Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750703 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US9872837 PURDUE PHARMA LP Tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US9861584 PURDUE PHARMA LP Tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US9572779 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US8808740 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 20 November, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of HYSINGLA ER before it's patent expiration?
More Information on Dosage

63. List of Imbruvica drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10004746 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(8 years from now)

US9801881 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK)
Jun, 2031

(8 years from now)

US8999999 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(8 years from now)

US9125889 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(8 years from now)

US9814721 PHARMACYCLICS INC Use of inhibitors of bruton'S tyrosine kinase (BTK)
Jun, 2031

(8 years from now)

US10751342 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(8 years from now)

US10653696 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK)
Jun, 2031

(8 years from now)

US10478439 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(8 years from now)

US9801883 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(8 years from now)

US8754090 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Jun, 2031

(8 years from now)

US10016435 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Jun, 2031

(8 years from now)

US10478439

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US8999999

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US9125889

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US9801881

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK)
Dec, 2031

(8 years from now)

US9814721

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton'S tyrosine kinase (BTK)
Dec, 2031

(8 years from now)

US9801883

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US10016435

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US10751342

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US8754090

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

US10653696

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK)
Dec, 2031

(8 years from now)

US10004746

(Pediatric)

PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk)
Dec, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
M Jan 25, 2022
New Patient Population (NPP) Aug 24, 2025
Orphan Drug Exclusivity (ODE) Aug 2, 2024
Pediatric Exclusivity (PED) Feb 24, 2026

Drugs and Companies using IBRUTINIB ingredient

Market Authorisation Date: 13 November, 2013

Treatment: Treatment of small lymphocytic lymphoma; Treatment of chronic lymphocytic leukemia; Treatment of small lymphocytic lymphoma with 17p deletion; Treatment of chronic lymphocytic leukemia with 17p deletion; Treatment of waldenstrom's macroglobulinemia; Treatment of marginal zone lymphoma; Treatment of relapsed or refractory small lymphocytic lymphoma; Treatment of relapsed or refractory chronic lymphocytic leukemia; Treatment of mantle cell lymphoma; Treatment of chronic graft versus host disease after failure of one or more lines of systemic therapy; Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma; Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma with 17p deletion

Dosage: CAPSULE;ORAL

How can I launch a generic of IMBRUVICA before it's patent expiration?
More Information on Dosage

64. List of Ingrezza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8039627 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 11, 2022

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 11 April, 2017

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's patent expiration?
More Information on Dosage

65. List of Inomax drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295802 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(7 years from now)

US8776795 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(7 years from now)

US8291904 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(7 years from now)

US9408993 MALLINCKRODT HOSP Nitric oxide delivery device
Jan, 2031

(7 years from now)

US8776794 MALLINCKRODT HOSP Nitric oxide delivery device
Jan, 2031

(7 years from now)

US9265911 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(7 years from now)

US8573210 MALLINCKRODT HOSP Nitric oxide delivery device
Jan, 2031

(7 years from now)

US8573209 MALLINCKRODT HOSP Gas delivery device and system
Jan, 2031

(7 years from now)

US8573209

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(8 years from now)

US9295802

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(8 years from now)

US8291904

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(8 years from now)

US8776795

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(8 years from now)

US9265911

(Pediatric)

MALLINCKRODT HOSP Gas delivery device and system
Jul, 2031

(8 years from now)

US9408993

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device
Jul, 2031

(8 years from now)

US8776794

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device
Jul, 2031

(8 years from now)

US8573210

(Pediatric)

MALLINCKRODT HOSP Nitric oxide delivery device
Jul, 2031

(8 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 23 December, 1999

Treatment: A method of providing a predetermined concentration of nitric oxide to a patient; A method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery to patient; A method of treating hypoxic respiratory failure by verifying gas information of nitric oxide prior to delivery to patient

Dosage: GAS;INHALATION

How can I launch a generic of INOMAX before it's patent expiration?
More Information on Dosage

66. List of Intrarosa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268806 MILLICENT Pharmaceutical compositions
Mar, 2031

(8 years from now)

Drugs and Companies using PRASTERONE ingredient

Market Authorisation Date: 16 November, 2016

Treatment: NA

Dosage: INSERT;VAGINAL

More Information on Dosage

67. List of Invega Sustenna drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439906 JANSSEN PHARMS Dosing regimen associated with long acting injectable paliperidone esters
Jan, 2031

(7 years from now)

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 31 July, 2009

Treatment: Treatment of schizophrenia; Treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; Dosing regimen for the treatment of schizoaffective disorder in adults as a monotherapy and as an adjunct to mood stabilizers or antidepressants by administering two loading doses of paliperidone palmitate followed by maintenance dose(s); Dosing regimen for the treatment of schizophrenia in adults by administering two loading doses of paliperidone palmitate followed by maintenance dose(s)

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of INVEGA SUSTENNA before it's patent expiration?
More Information on Dosage

68. List of Invokana drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617668 JANSSEN PHARMS Pharmaceutical formulations
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Sep 27, 2022

Drugs and Companies using CANAGLIFLOZIN ingredient

Market Authorisation Date: 29 March, 2013

Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; Treatment of type 2 diabetes mellitus with 300 mg canagliflozin per day; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus with 100 mg canagliflozin per day; Treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

How can I launch a generic of INVOKANA before it's patent expiration?
More Information on Dosage

69. List of Ionsys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8301238 THE MEDICINES CO Two-part electrotransport device
Sep, 2031

(8 years from now)

US9364656 THE MEDICINES CO Method of storing an electrotransport drug delivery device
Sep, 2031

(8 years from now)

US9731121 THE MEDICINES CO Switch validation circuit and method
Oct, 2031

(8 years from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: Method for iontophoretic transdermal delivery of fentanyl hydrochloride

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

More Information on Dosage

70. List of Isentress drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649311

(Pediatric)

MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Apr, 2031

(8 years from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 12 October, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ISENTRESS before it's patent expiration?
More Information on Dosage

71. List of Isturisa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9434754 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 6, 2025
Orphan Drug Exclusivity (ODE) Mar 6, 2027

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

NCE-1 date: March, 2024

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease

Dosage: TABLET;ORAL

More Information on Dosage

72. List of Jelmyto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9950069 UROGEN PHARMA Material and method for treating internal cavities
Jan, 2031

(7 years from now)

US9040074 UROGEN PHARMA Material and method for treating internal cavities
Jan, 2031

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 15, 2027
New Product (NP) Apr 15, 2023

Drugs and Companies using MITOMYCIN ingredient

Market Authorisation Date: 15 April, 2020

Treatment: NA

Dosage: POWDER;PYELOCALYCEAL

More Information on Dosage

73. List of Jevtana Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927592

(Pediatric)

SANOFI AVENTIS US Antitumoral use of cabazitaxel
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
M Dec 18, 2023

Drugs and Companies using CABAZITAXEL ingredient

Market Authorisation Date: 17 June, 2010

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of JEVTANA KIT before it's patent expiration?
More Information on Dosage

74. List of Juluca drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10426780 VIIV HLTHCARE Antiviral therapy
Jan, 2031

(7 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 November, 2017

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of JULUCA before it's patent expiration?
More Information on Dosage

75. List of Keppra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802142 UCB INC Pharmaceutical compositions comprising levetiracetam and process for their preparation
Jun, 2031

(8 years from now)

US8802142

(Pediatric)

UCB INC Pharmaceutical compositions comprising levetiracetam and process for their preparation
Dec, 2031

(8 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 30 November, 1999

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of KEPPRA before it's patent expiration?
More Information on Dosage

76. List of Kisqali drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415355 NOVARTIS Pyrrolopyrimidine compounds and their uses
Mar, 2031

(8 years from now)

US9193732 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 13, 2022
New Patient Population (NPP) Dec 10, 2024

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 13 March, 2017

Treatment: In combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; In combination with fulvestrant for the treatment of postmenopausal women with hr-positive, her2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy; In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; In combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

How can I launch a generic of KISQALI before it's patent expiration?
More Information on Dosage

77. List of Kisqali Femara Co-pack (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415355 NOVARTIS Pyrrolopyrimidine compounds and their uses
Mar, 2031

(8 years from now)

US9193732 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 13, 2022
New Patient Population (NPP) Dec 10, 2024

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 04 May, 2017

Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; As initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

How can I launch a generic of KISQALI FEMARA CO-PACK (COPACKAGED) before it's patent expiration?
More Information on Dosage

78. List of Kyleena drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9668912 BAYER HLTHCARE Inserter
Apr, 2031

(8 years from now)

US10987244 BAYER HLTHCARE Inserter
Apr, 2031

(8 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 16 September, 2016

Treatment: NA

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage

79. List of Kynmobi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11419769 SUNOVION PHARMS INC Sublingual films
Dec, 2031

(8 years from now)

US8846074 SUNOVION PHARMS INC Sublingual films
Dec, 2031

(8 years from now)

US8414922 SUNOVION PHARMS INC Sublingual films
Dec, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 21, 2023

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 May, 2020

Treatment: Treatment of 'off' episodes in patients with parkinson's disease

Dosage: FILM;SUBLINGUAL

More Information on Dosage

80. List of Latuda drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9827242 SUNOVION PHARMS INC Method of treatment for mental disorders
May, 2031

(8 years from now)

US9259423 SUNOVION PHARMS INC Method of treatment for mental disorders
May, 2031

(8 years from now)

US9259423

(Pediatric)

SUNOVION PHARMS INC Method of treatment for mental disorders
Nov, 2031

(8 years from now)

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 October, 2010

Treatment: Treatment of schizophrenia with improvement in attention function in schizophrenia; Treatment of bipolar depression with improvement in attention function in bipolar disorder; Treatment of schizophrenia or bipolar depression with improvement in attention function in schizophrenia and/or bipolar disorder

Dosage: TABLET;ORAL

How can I launch a generic of LATUDA before it's patent expiration?
More Information on Dosage

81. List of Letairis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549926 GILEAD Compositions and methods of treating pulmonary hypertension
Oct, 2031

(8 years from now)

Drugs and Companies using AMBRISENTAN ingredient

Market Authorisation Date: 15 June, 2007

Treatment: For the treatment of pulmonary arterial hypertension (pah) in combination with tadalafil, wherein the weight ratio of ambrisentan to tadalafil is about 1:2 to about 1:3

Dosage: TABLET;ORAL

How can I launch a generic of LETAIRIS before it's patent expiration?
More Information on Dosage

82. List of Linzess drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8933030 ALLERGAN Treatments for gastrointestinal disorders
Feb, 2031

(8 years from now)

US10702576 ALLERGAN Stable formulations of linaclotide
Aug, 2031

(8 years from now)

US10675325 ALLERGAN Stable formulations of linaclotide
Aug, 2031

(8 years from now)

US8748573 ALLERGAN Formulations comprising linaclotide
Oct, 2031

(8 years from now)

US8802628 ALLERGAN Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration
Oct, 2031

(8 years from now)

Drugs and Companies using LINACLOTIDE ingredient

Market Authorisation Date: 30 August, 2012

Treatment: Method of treating chronic idiopathic constipation in adult patients.; Method of treating irritable bowel syndrome with constipation in adult patients.

Dosage: CAPSULE;ORAL

How can I launch a generic of LINZESS before it's patent expiration?
More Information on Dosage

83. List of Livmarli drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11260053 MIRUM Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 29, 2026
Orphan Drug Exclusivity (ODE) Sep 29, 2028

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: September, 2025

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)

Dosage: SOLUTION;ORAL

More Information on Dosage

84. List of Lupron Depot drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921326 ABBVIE ENDOCRINE INC Sustained-release composition and method for producing the same
Feb, 2031

(8 years from now)

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 22 December, 1995

Treatment: Palliative treatment of prostate cancer

Dosage: INJECTABLE;INJECTION

More Information on Dosage

85. List of Lybalvi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9119848 ALKERMES INC Morphinan derivatives for the treatment of drug overdose
Aug, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241425 ALKERMES INC Composition for treating mental illness
Aug, 2031

(8 years from now)

US11185541 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US10716785 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US10300054 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US9126977 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US9517235 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

US11351166 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 28, 2026

Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan; Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan; Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduction of the adverse metabolic profile; Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduction of the adverse metabolic profile

Dosage: TABLET;ORAL

More Information on Dosage

86. List of Lynparza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859562 ASTRAZENECA Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(8 years from now)

Drugs and Companies using OLAPARIB ingredient

Market Authorisation Date: 19 December, 2014

Treatment: Maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; Treatment of deleterious or suspected deleterious germline brca-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy; Treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; Treatment of hr-positive, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and with endocrine therapy or are inappropriate for endocrine therapy; Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; Maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; Maintenance treatment of brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; Treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Adjuvant treatment of patients with gbrca-mutated human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy

Dosage: CAPSULE;ORAL

How can I launch a generic of LYNPARZA before it's patent expiration?
More Information on Dosage

87. List of Makena drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446440 COVIS Needle assisted injection device having reduced trigger force
Aug, 2031

(8 years from now)

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Market Authorisation Date: 03 February, 2011

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS

How can I launch a generic of MAKENA before it's patent expiration?
More Information on Dosage

88. List of Mavyret drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9586978

(Pediatric)

ABBVIE INC Anti-viral compounds
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 3, 2022
M Apr 10, 2023
New Dosing Schedule (D) Sep 26, 2022
Orphan Drug Exclusivity (ODE) Jun 10, 2028
Pediatric Exclusivity (PED) Mar 26, 2023

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: March, 2022

Market Authorisation Date: 10 June, 2021

Treatment: NA

Dosage: PELLETS;ORAL

More Information on Dosage

89. List of Mektovi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Jul, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 27, 2023
Orphan Drug Exclusivity (ODE) Jun 27, 2025

Drugs and Companies using BINIMETINIB ingredient

NCE-1 date: June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Indicated in combination with encorafenib for the treatment of melanoma mediated by a b-raf protein kinase

Dosage: TABLET;ORAL

How can I launch a generic of MEKTOVI before it's patent expiration?
More Information on Dosage

90. List of Minocin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9084802 REMPEX Tetracycline compositions
May, 2031

(8 years from now)

US9278105 REMPEX Tetracycline compositions
May, 2031

(8 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Treatment: Method of treating bacterial infections

Dosage: INJECTABLE;INJECTION

How can I launch a generic of MINOCIN before it's patent expiration?
More Information on Dosage

91. List of Mirena drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10987244 BAYER HLTHCARE Inserter
Apr, 2031

(8 years from now)

US9668912 BAYER HLTHCARE Inserter
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Dosing Schedule (D) Aug 20, 2023

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 06 December, 2000

Treatment: NA

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage

92. List of Mirvaso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9861631 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(8 years from now)

US8513247 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(8 years from now)

US8513249 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(8 years from now)

US9861632 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(8 years from now)

US10201517 GALDERMA LABS LP Brimonidine gel compositions and methods of use
Jun, 2031

(8 years from now)

US8163725 GALDERMA LABS LP Gel compositions and methods of use
Jun, 2031

(8 years from now)

US8053427 GALDERMA LABS LP Brimonidine gel composition
Jun, 2031

(8 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 23 August, 2013

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

How can I launch a generic of MIRVASO before it's patent expiration?
More Information on Dosage

93. List of Mounjaro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Feb, 2031

(8 years from now)

US9402957 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Jun, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: May, 2026

Market Authorisation Date: 13 May, 2022

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

94. List of Mulpleta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427402 SHIONOGI INC Preparation for improving solubility of poorly soluble drug
Sep, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 31, 2023

Drugs and Companies using LUSUTROMBOPAG ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 31 July, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

95. List of Multaq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8602215 SANOFI AVENTIS US Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
Jun, 2031

(8 years from now)

Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient

Market Authorisation Date: 01 July, 2009

Treatment: Management of risk of dronedarone/beta-blocker interaction in patients in sinus rythm with a history of paroxysmal or persistent af

Dosage: TABLET;ORAL

How can I launch a generic of MULTAQ before it's patent expiration?
More Information on Dosage

96. List of Mytesi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585868 NAPO PHARMS INC Methods and compositions for treating HIV-associated diarrhea
Oct, 2031

(8 years from now)

US8962680 NAPO PHARMS INC Methods and compositions for treating HIV-associated diarrhea
Oct, 2031

(8 years from now)

Drugs and Companies using CROFELEMER ingredient

Market Authorisation Date: 31 December, 2012

Treatment: Symptomatic relief of non-infectious diarrhea

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage

97. List of Naloxone Hydrochloride (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9022022 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(8 years from now)

US10322239 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(8 years from now)

US9474869 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(8 years from now)

US8939943 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(8 years from now)

US9814838 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2031

(8 years from now)

US10143792 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
May, 2031

(8 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 February, 2022

Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

98. List of Nerlynx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8669273 PUMA BIOTECH Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
Jul, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 17, 2022
New Indication (I) Feb 25, 2023
New Dosing Schedule (D) Jun 28, 2024

Drugs and Companies using NERATINIB MALEATE ingredient

NCE-1 date: July, 2021

Market Authorisation Date: 17 July, 2017

Treatment: Use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting

Dosage: TABLET;ORAL

How can I launch a generic of NERLYNX before it's patent expiration?
More Information on Dosage

99. List of Nexiclon Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623409 ATHENA Clonidine formulation
Sep, 2031

(8 years from now)

Drugs and Companies using CLONIDINE ingredient

Market Authorisation Date: 03 December, 2009

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

100. List of Nithiodote drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8496973 HOPE PHARMS Sodium thiosulfate-containing pharmaceutical compositions
Mar, 2031

(8 years from now)

US8568793 HOPE PHARMS Sodium nitrite-containing pharmaceutical compositions
Dec, 2031

(8 years from now)

Drugs and Companies using SODIUM NITRITE; SODIUM THIOSULFATE ingredient

Market Authorisation Date: 14 January, 2011

Treatment: Treatment of acute cyanide poisoning that is judged to be life threatening

Dosage: SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS

More Information on Dosage

101. List of Noxafil drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9358297 MERCK SHARP DOHME Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin
Jun, 2031

(8 years from now)

US9023790 MERCK SHARP DOHME Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin
Jul, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) May 31, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2028
New Indication (I) Jun 17, 2024

Drugs and Companies using POSACONAZOLE ingredient

Market Authorisation Date: 13 March, 2014

Treatment: Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised; Prophylaxis of invasive aspergillus and candida infections

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of NOXAFIL before it's patent expiration?
More Information on Dosage

102. List of Nurtec Odt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8314117 BIOHAVEN IRELAND CGRP receptor antagonists
Feb, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 27, 2025
New Indication (I) May 27, 2024

Drugs and Companies using RIMEGEPANT SULFATE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 27 February, 2020

Treatment: Acute treatment of migraine with or without aura in adults; Preventive treatment of episodic migraine in adults

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

103. List of Nuzyra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314475 PARATEK PHARMS INC Oral and injectable formulations of tetracycline compounds
Mar, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 2, 2023
Generating Antibiotic Incentives Now (GAIN) Oct 2, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: October, 2027

Market Authorisation Date: 02 October, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

104. List of Ofirmev drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399012 MALLINCKRODT HOSP Reduced dose intravenous acetaminophen
Sep, 2031

(8 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Market Authorisation Date: 02 November, 2010

Treatment: Modified dosing regimen for the reduction of fever; Modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioid analgesics

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of OFIRMEV before it's patent expiration?
More Information on Dosage

105. List of Opzelura drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10758543 INCYTE CORP Topical formulation for a JAK inhibitor
May, 2031

(8 years from now)

US10869870 INCYTE CORP Topical formulation for a JAK inhibitor
May, 2031

(8 years from now)

US11219624 INCYTE CORP Topical formulation for a JAK inhibitor
May, 2031

(8 years from now)

US10758543

(Pediatric)

INCYTE CORP Topical formulation for a JAK inhibitor
Nov, 2031

(8 years from now)

US11219624

(Pediatric)

INCYTE CORP Topical formulation for a JAK inhibitor
Nov, 2031

(8 years from now)

US10869870

(Pediatric)

INCYTE CORP Topical formulation for a JAK inhibitor
Nov, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 21, 2024
New Indication (I) Jul 18, 2025
Pediatric Exclusivity (PED) Mar 21, 2025

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Market Authorisation Date: 21 September, 2021

Treatment: For topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable

Dosage: CREAM;TOPICAL

More Information on Dosage

106. List of Orenitram drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8349892 UNITED THERAP Solid formulations of prostacyclin analogs
Jan, 2031

(7 years from now)

US8747897 UNITED THERAP Osmotic drug delivery system
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 18, 2022
Orphan Drug Exclusivity (ODE) Oct 18, 2026

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Market Authorisation Date: 20 December, 2013

Treatment: A method of treating pulmonary hypertension and pulmonary arterial hypertension by administering an oral osmotic pharmaceutical dosage form; A method of oral delivery of treprostinil comprising administering an oral osmotic pharmaceutical dosage form

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ORENITRAM before it's patent expiration?
More Information on Dosage

107. List of Otrexup drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8814834 OTTER PHARMS Injector safety device
May, 2031

(8 years from now)

Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 11 October, 2013

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

108. List of Ozempic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Jan 16, 2023
New Chemical Entity Exclusivity (NCE) Dec 5, 2022
New Dosing Schedule (D) Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 05 December, 2017

Treatment: Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of OZEMPIC before it's patent expiration?
More Information on Dosage

109. List of Parsabiv drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8999932 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Feb, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 7, 2022

Drugs and Companies using ETELCALCETIDE ingredient

NCE-1 date: February, 2021

Market Authorisation Date: 07 February, 2017

Treatment: A method of treating secondary hyperparathyroidism (shpt)

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of PARSABIV before it's patent expiration?
More Information on Dosage

110. List of Pifeltro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 30, 2023
New Indication (I) Sep 19, 2022
New Patient Population (NPP) Jan 27, 2025

Drugs and Companies using DORAVIRINE ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: For use in combination with other antiretroviral agents for the treatment of hiv-1 as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to doravirine; For use in combination with other antiretroviral agents for the treatment of hiv-1 infection in adult patients with no prior antiretroviral treatment history; For use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen if virologically suppressed

Dosage: TABLET;ORAL

More Information on Dosage

111. List of Pliaglis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350180 TARO PHARMS Solid-forming local anesthetic formulations for pain control
Jan, 2031

(7 years from now)

US10603293 TARO PHARMS Solid-forming local anesthetic formulations for pain control
Jan, 2031

(7 years from now)

US10751305 TARO PHARMS Solid-forming topical formulations for pain control
Jan, 2031

(7 years from now)

Drugs and Companies using LIDOCAINE; TETRACAINE ingredient

Market Authorisation Date: 29 June, 2006

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage

112. List of Pomalyst drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8828427 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Jun, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828427

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Dec, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
M Nov 20, 2023
Orphan Drug Exclusivity (ODE) May 14, 2027
Pediatric Exclusivity (PED) May 20, 2024

Drugs and Companies using POMALIDOMIDE ingredient

Market Authorisation Date: 08 February, 2013

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of POMALYST before it's patent expiration?
More Information on Dosage

113. List of Pradaxa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034822 BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds
Jan, 2031

(7 years from now)

US9034822

(Pediatric)

BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds
Jul, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Jun 21, 2024
Pediatric Exclusivity (PED) Dec 21, 2024

Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient

Market Authorisation Date: 19 October, 2010

Treatment: Method of reversing the anticoagulant effect of dabigatran using idarucizumab

Dosage: CAPSULE;ORAL

How can I launch a generic of PRADAXA before it's patent expiration?
More Information on Dosage

114. List of Proair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(8 years from now)

US9731087 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(8 years from now)

US10124131 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US9216260 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(8 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

115. List of Proair Hfa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11395889 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US10695512 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US10022509 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(8 years from now)

US9808587 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US10086156 TEVA BRANDED PHARM Dose counter for inhaler and method for counting doses
May, 2031

(8 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(8 years from now)

US9463289 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(8 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 29 October, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of PROAIR HFA before it's patent expiration?
More Information on Dosage

116. List of Pyrukynd drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8785450 AGIOS PHARMS INC Therapeutic compounds and compositions
Feb, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 17, 2027

Drugs and Companies using MITAPIVAT SULFATE ingredient

NCE-1 date: February, 2026

Market Authorisation Date: 17 February, 2022

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

117. List of Qnasl drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188811 TEVA BRANDED PHARM Nasal spray device
Oct, 2031

(8 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 23 March, 2012

Treatment: NA

Dosage: AEROSOL, METERED;NASAL

More Information on Dosage

118. List of Quillichew Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8287903 NEXTWAVE PHARMS Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 December, 2015

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

How can I launch a generic of QUILLICHEW ER before it's patent expiration?
More Information on Dosage

119. List of Quillivant Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8563033 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US8778390 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US8465765 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US8287903 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US9040083 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US8956649 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 September, 2012

Treatment: Treating a patient having a condition susceptible to treatment with methylphenidate, such as adhd, by administering the formulation recited in claims 1 or 2; Treatment of a patient by administering the formulation recited in claim 1 or claim 23; Method of treating attention deficit hyperactivity disorder by administering the composition of claim 1

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

How can I launch a generic of QUILLIVANT XR before it's patent expiration?
More Information on Dosage

120. List of Qulipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9499545 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: September, 2025

Market Authorisation Date: 28 September, 2021

Treatment: Preventive treatment of episodic migraine in adults

Dosage: TABLET;ORAL

More Information on Dosage

121. List of Qvar 40 drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808587 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US10695512 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(8 years from now)

US10022509 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(8 years from now)

US9463289 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(8 years from now)

US10086156 TEVA BRANDED PHARM Dose counter for inhaler and method for counting doses
May, 2031

(8 years from now)

US11395889 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 15 September, 2000

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of QVAR 40 before it's patent expiration?
More Information on Dosage

122. List of Qvar Redihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10022510 NORTON WATERFORD Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(8 years from now)

US10086156 NORTON WATERFORD Dose counter for inhaler and method for counting doses
May, 2031

(8 years from now)

US10022509 NORTON WATERFORD Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(8 years from now)

US10695512 NORTON WATERFORD Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US11395889 NORTON WATERFORD Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(8 years from now)

US8931476 NORTON WATERFORD Inhaler
Jul, 2031

(8 years from now)